Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families
Metrics: PDF 1310 views | HTML 2439 views | ?
Marie-Christine Pouliot1, Charu Kothari1, Charles Joly-Beauparlant1, Yvan Labrie1, Geneviève Ouellette1, Jacques Simard1, Arnaud Droit1 and Francine Durocher1
1CHU de Québec Research Centre-Université Laval, Department of Molecular Medicine, Québec, Canada
Francine Durocher, email: [email protected]
Keywords: hereditary breast cancer, high-risk BRCA1/2/X families, gene expression, RNA-seq, lymphoblastoid cell lines
Received: September 28, 2016 Accepted: July 17, 2017 Published: August 12, 2017
Approximately 25% of hereditary breast cancer cases are associated with a strong familial history which can be explained by mutations in BRCA1 or BRCA2 and other lower penetrance genes. The remaining high-risk families could be classified as BRCAX (non-BRCA1/2) families.
Gene expression involving alternative splicing represents a well-known mechanism regulating the expression of multiple transcripts, which could be involved in cancer development. Thus using RNA-seq methodology, the analysis of transcriptome was undertaken to potentially reveal transcripts implicated in breast cancer susceptibility and development.
RNA was extracted from immortalized lymphoblastoid cell lines of 117 women (affected and unaffected) coming from BRCA1, BRCA2 and BRCAX families. Anova analysis revealed a total of 95 transcripts corresponding to 85 different genes differentially expressed (Bonferroni corrected p-value <0.01) between those groups. Hierarchical clustering allowed distinctive subgrouping of BRCA1/2 subgroups from BRCAX individuals. We found 67 transcripts, which could discriminate BRCAX from BRCA1/BRCA2 individuals while 28 transcripts discriminate affected from unaffected BRCAX individuals.
To our knowledge, this represents the first study identifying transcripts differentially expressed in lymphoblastoid cell lines from major classes of mutation-related breast cancer subgroups, namely BRCA1, BRCA2 and BRCAX. Moreover, some transcripts could discriminate affected from unaffected BRCAX individuals, which could represent potential therapeutic targets for breast cancer treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.